Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

October 04, 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging Trial

News Conference News ESC Heart Failure 2023

Amyloid Removal Looks Possible in ATTR Cardiomyopathy Imaging Trial

May 23, 2023

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

News Conference News ACC 2021

Omecamtiv Mecarbil Has Biggest Benefit at Lowest EFs

May 18, 2021

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

News Conference News AHA 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

November 13, 2020

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

News Conference News ESC 2018

My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More

September 14, 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

News Conference News ESC 2018

ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More

August 20, 2018

News Conference News AHA 2016

Early Vasodilator Therapy Not the Answer for Improving Long-term Outcomes After Acute Decompensated Heart Failure

November 13, 2016

News Conference News ESC 2016

New Cardio-Oncology Position Statement Reviews Cardiovascular Side Effects of Cancer Therapies and Calls for Further Study

August 27, 2016

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

August 31, 2015

News Conference News ESC 2015

Danish Registry Study Shows Potential of Stroke Risk Score in Heart Failure Patients

August 31, 2015

News Conference News Cell Therapy 2012

Novel Strategies Advance Cell Therapy for Cardiomyopathy

February 05, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.